PARP1 and neoplasm: synthesized a highly selective PARP/BRD4 dual inhibitor, which displayed good synergistic anti-tumor efficacy in BRCA wild-type PDAC cells by blocking the cell cycle progression, inhibiting DNA damage repair, and promoting autophagy-related cell death (157).